The Experts below are selected from a list of 373320 Experts worldwide ranked by ideXlab platform

Laura E. Gibbons - One of the best experts on this subject based on the ideXlab platform.

Shanghai - One of the best experts on this subject based on the ideXlab platform.

  • Reliability and Validity of Chinese Version of Alzheimer’s Disease Assessment Scale-Cognitive Part
    Chinese journal of clinical psychology, 2009
    Co-Authors: Li Xia, Xiao Ze-ping, Xiao Shi-fu, Shanghai
    Abstract:

    Objective: To evaluate the validity and reliability of the Chinese version of Alzheimer’s Disease Assessment Scale-Cognitive part (ADAS-Cog). Methods: 135 subjects with Alzheimer’s Disease (AD) and 78 normal control subjects were assessed by ADAS-Cog. 95 subjects with AD were retested after 4 weeks. The test-retest reliability, parallel validity and criterion validity were examined. Results: Except the item of concentration, the other item scores of ADAS-Cog and its total score were significantly correlated to retest ones (P0.001), ADAS-Cog total was correlated to the scores of MMSE, ADL and NPI (P0.01). By the diagnostic criterion for AD from Diagnostic and Statistical Manual of Mental Disorders, the fourth version (DSM-IV), optimal cut-off points of ADAS-Cog was 15.5, with sensitivity 91.9% and specificity 89.5%, and the area under the curve (AUC) was 0.95. Conclusion: With satisfactory reliability and validity, ADAS-Cog can be applied to clinical researches or longitudinal studies on AD.

Richard C. Mohs - One of the best experts on this subject based on the ideXlab platform.

  • Alzheimer's Disease Assessment Scale: The Validation of the Scale in Greece in Elderly Demented Patients and Normal Subjects
    Dementia and geriatric cognitive disorders, 1997
    Co-Authors: Magda Tsolaki, Kostas Fountoulakis, Evangelia Nakopoulou, Aristides Kazis, Richard C. Mohs
    Abstract:

    Introduction: The Alzheimer Disease Assessment Scale (ADAS) is a scale specifically structured for the Assessment of the cognitive decline and behavioral disorder seen in Alzheimer Disease (AD) patien

  • development of cognitive instruments for use in clinical trials of antidementia drugs additions to the alzheimer s Disease Assessment scale that broaden its scope
    Alzheimer Disease & Associated Disorders, 1997
    Co-Authors: Richard C. Mohs, David S Knopman, Ronald C Petersen, Steven H Ferris, Chris Ernesto, Michael Grundman, Mary Sano, Linas A Bieliauskas, David S Geldmacher, Christopher M Clark
    Abstract:

    SummaryThe cognitive Assessment protocol of the Alzheimer's Disease Cooperative Study (ADCS) was designed to evaluate the reliability and validity of cognitive Assessment measures that might be valuable additions to the Alzheimer's Disease Assessment Scale (ADAS) or other concise batteries used in a

  • The Alzheimer’s Disease Assessment Scale: Modifications That Can Enhance its Use in Future Clinical Trials
    Alzheimer Disease, 1997
    Co-Authors: Richard C. Mohs, Deborah B. Marin, Cynthia R. Green, Kenneth L. Davis
    Abstract:

    The Alzheimer’s Disease Assessment Scale (ADAS) is widely used in clinical trials of potential treatments for Alzheimer’s Disease (AD). The cognitive portion of the ADAS (ADAS-Cog) consists of 11 items designed to assess the severity of memory, language, praxis and orientation impairments. The noncognitive portion of the ADAS (ADAS-Non-Cog) consists of 10 clinician rated items assessing the severity of depressive symptoms, psychosis, agitation, attention and tremors. These items are described in previous publications (Mohs et al., 1982; Rosen et al., 1984), and longitudinal data have demonstrated that the cognitive portion of the scale measures progressive cognitive impairment across a broad range of dementia severity (Stern et al., 1994). The ADAS-Cog has been used as the principal measure of cognitive outcome in several multicenter clinical trials of potential treatments for AD, including the trials of tacrine (Farlow et al., 1992; Knapp et al., 1994).

  • The Alzheimer's Disease Assessment Scale
    International psychogeriatrics, 1996
    Co-Authors: Richard C. Mohs
    Abstract:

    This article reviews longitudinal data collected from patients with Alzheimer's Disease (AD) that are relevant to the design and interpretation of clinical treatment trials. Longitudinal data from patients tested with the Alzheimer's Disease Assessment Scale demonstrate that cognitive symptoms, including memory loss, dysphasia, and dyspraxia, worsen relentlessly over time with the rate of change depending upon baseline dementia severity. Noncognitive symptoms, such as agitation, depressed mood, and psychosis, are episodic, do not necessarily worsen over time, and tend not to be highly correlated with one another. The reliability of cognitive change measures increases with follow-up duration so that the likelihood of detecting drug effects on the rate of cognitive deterioration is greater with longer treatment trials. Functional measures of activities of daily living are difficult to standardize for AD patients but are important for determining the overall clinical and economic impact of AD treatments.

Sien Deng - One of the best experts on this subject based on the ideXlab platform.

  • An approach for estimating item sensitivity to within-person change over time: An illustration using the Alzheimer's Disease Assessment Scale-Cognitive subscale (ADAS-Cog).
    Psychological assessment, 2016
    Co-Authors: N. Maritza Dowling, Daniel M. Bolt, Sien Deng
    Abstract:

    When Assessments are primarily used to measure change over time, it is important to evaluate items according to their sensitivity to change, specifically. Items that demonstrate good sensitivity to between-person differences at baseline may not show good sensitivity to change over time, and vice versa. In this study, we applied a longitudinal factor model of change to a widely used cognitive test designed to assess global cognitive status in dementia, and contrasted the relative sensitivity of items to change. Statistically nested models were estimated introducing distinct latent factors related to initial status differences between test-takers and within-person latent change across successive time points of measurement. Models were estimated using all available longitudinal item-level data from the Alzheimer's Disease Assessment Scale-Cognitive subscale, including participants representing the full-spectrum of Disease status who were enrolled in the multisite Alzheimer's Disease Neuroimaging Initiative. Five of the 13 Alzheimer's Disease Assessment Scale-Cognitive items demonstrated noticeably higher loadings with respect to sensitivity to change. Attending to performance change on only these 5 items yielded a clearer picture of cognitive decline more consistent with theoretical expectations in comparison to the full 13-item scale. Items that show good psychometric properties in cross-sectional studies are not necessarily the best items at measuring change over time, such as cognitive decline. Applications of the methodological approach described and illustrated in this study can advance our understanding regarding the types of items that best detect fine-grained early pathological changes in cognition. (PsycINFO Database Record

Keith Wesnes - One of the best experts on this subject based on the ideXlab platform.